| Fri, 26 May 2017 12:31:02: | Safety profile will help bring ozanimod to multiple sclerosis market, says Celgene
|
| Fri, 26 May 2017 09:36:34: | Gottlieb ends FDA hiring freeze, lays out R&D priorities
|
| Thu, 25 May 2017 19:47:01: | Chutes & Ladders—Alexion’s C-suite overhaul involves CFO, R&D head
|
| Thu, 25 May 2017 13:30:24: | Harpoon Therapeutics hits $45M in series B for I-O work
|
| Thu, 25 May 2017 13:06:19: | NEJM paper buoys GW Pharma as it eyes FDA filing for cannabis drug Epidiolex
|
| Thu, 25 May 2017 12:22:21: | Months after trial setbacks, Merck licenses Teijin Alzheimer’s candidate
|
| Thu, 25 May 2017 09:41:34: | Redx stock suspended after loan repayment spat escalates
|
| Thu, 25 May 2017 08:14:40: | FDA panel backs Puma’s neratinib, clearing path to approval
|
| Thu, 25 May 2017 07:42:50: | WuXi Biologics guns for $500M Hong Kong IPO
|
| Wed, 24 May 2017 13:33:21: | Funding uncertainty could dent U.K.'s role as Euro biotech hub, says BIA
|
| Wed, 24 May 2017 13:16:39: | Takeda and NEA back $39M series A for GI biotech OrphoMed
|
| Wed, 24 May 2017 12:54:13: | ???????Cel-Sci, in trying to escape clinical hold, creates new problems for Multikine R&D program at the FDA
|
| Wed, 24 May 2017 09:56:02: | Pierre Fabre buys up Igenica preclinical I-O meds
|
| Wed, 24 May 2017 08:35:19: | Debiopharm buys ImmunoGen ADC to grow cancer pipeline
|
| Tue, 23 May 2017 13:14:34: | Cancer resistance firm TP Therapeutics reaps $45M in third round
|
| Tue, 23 May 2017 12:34:06: | Bioverativ to buy True North for $400M upfront
|
| Tue, 23 May 2017 12:24:13: | China’s CANbridge Life Sciences gains $25M series B, plots new cancer trials
|
| Tue, 23 May 2017 10:56:21: | Donald Trump’s healthcare budget outlines FDA, NIH cuts
|
| Tue, 23 May 2017 09:10:29: | Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection
|
| Mon, 22 May 2017 13:20:10: | Nektar pens sweetened Takeda cancer drugs deal
|
| Mon, 22 May 2017 12:45:12: | Celgene touts ozanimod MS data, but disability benefit weak over rival drug
|
| Mon, 22 May 2017 12:39:38: | Shock for Amgen and UCB as side effects undermine romo trial
|
| Mon, 22 May 2017 12:05:34: | Shire, Xenetic see hemophilia A candidate flunk key test
|
| Mon, 22 May 2017 12:00:40: | Merck KGaA, Ablynx push osteoarthritis asset toward clinic
|
| Mon, 22 May 2017 09:11:59: | La Jolla posts mixed bag of phase 3 data, raising hopes of FDA approval but calling commercial potential into question
|
